Governance

KHI Board of Directors Governance Update

Given KHI's growth over the past 10 years, a task force was launched in 2022 to assess its governance and oversight structure, recognizing the need to represent the diverse interests of a large member community. Recommendations addressed increased member engagement in KHI activities and projects, and clear prioritization criteria aligned with a multi-year strategy. As approved by the KHI Board of Directors, KHI's governance structure was revised to include four standing committees:

  • Strategy Committee
  • Biologics Committee (includes xenotransplantation; cellular, tissue, and gene therapies; and vaccines)
  • Devices Committee (includes devices, diagnostics, and digital health)
  • Drugs Committee

Recommendations also included defined charge and governance of these committees and frameworks for defining KHI strategy and approving KHI activities. The approved task force recommendations can be found here. KHI will begin implementation on January 1, 2023.

KHI Board of Directors Governance Task Force Executive Summary

For more details on the recommendations, read the Executive Summary here.

KHI Board of Directors Call for Applications

Interested in joining the KHI BOD? KHI seeks applications for members, who would serve a three-year term starting on January 1, 2023, renewable for one additional term. All BOD members serve through either the Biologics, Devices, Drugs, or Strategy Committees. KHI's governance structure includes a diverse and balanced BOD that reflects the composition and interests of stakeholders and members. In 2022, the KHI BOD will consider the following candidate profiles for the Biologics, Devices, Drugs, and Strategy Committees:

  • Patient advocates with experience in kidney diseases and related conditions
  • Representatives from small, mid, and large-sized private sector companies that encompass the breadth of FDA's mission
  • Health professionals with expertise in kidney diseases who are members of the American Society of Nephrology
  • At-large representatives with diverse experiences developing kidney biologics, devices and drugs

Applications must be received by Friday, September 23, 2022, at 5:00 p.m. EDT. Applications must specify which KHI BOD committee the candidate intends to serve on. For more information on the role and application process, please visit the KHI BOD Call for Applications.

KHI Board of Directors (BOD)

The KHI BOD is charged with executing the consortium's mission and objectives. Meet the Board of Directors!

KHI Patient and Family Partnership Council (PFPC)

The KHI PFPC advises and makes recommendations on projects and other activities to ensure that the voice, experiences, and involvement of people with kidney diseases are included in the development of kidney drugs, devices, and biologics. Meet the Patient and Family Partnership Council!